Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031

Colorectal Cancer Market Overview

The total number of cases affected by colorectal cancer was 3,183,569 in 2021. The number of cases is expected to grow at an AGR of more than 3% during the forecast period. Colorectal cancer, also referred as bowel cancer, is the cancer of the colon, rectum, or rectosigmoid junction. It is a type of gastrointestinal malignancy originating from either the colon or the rectum. Although both forms can be defined as colon or rectal cancers, depending on their origin, they are often merged because of the many biologically and clinically common features (American Cancer Society, 2020a). CRC is the second most lethal cancer after lung cancer, and the third most diagnosed malignant tumor worldwide.

Colorectal Cancer Market Outlook

For more insights on colorectal cancer market forecast data, download a free report sample

The Colorectal Cancer Epidemiology Analysis and Forecast market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex.

What are the market dynamics in the colorectal cancer market?

Although research studies have found several factors that can increase the risk of CRC, exactly how all those factors might cause this cancer remains unclear. A combination of genetic and environmental factors is most likely responsible for CRC. According to research in 2022, around a significant percentage of CRC cases develop for no clear reason, while a small percent seem to result from inherited syndromes, and a significant percent happen in family clusters. Among the non-modifiable risk factors of CRC are older age; male sex; being of African or Ashkenazi Jewish descent; family or personal history of CRC, polyps, or inflammatory bowel disease (IBD); and having an inherited syndrome due to gene mutations such as Lynch syndrome, also referred as hereditary non-polyposis CRC (HNPCC), and familial adenomatous polyposis. Many lifestyle-related modifiable factors are associated to CRC. Being overweight or obese, physical inactivity, eating a low-fiber and high-fat diet with red and processed meat regularly, sugary drinks, smoking, and alcohol are all linked to CRC (American Cancer Society, 2020b). In fact, the links between diet, exercise, and weight and CRC risk are some of the strongest for any type of cancer. In addition, type 2 diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF) are common comorbidities in CRC patients.

What are the key age segments in the colorectal cancer market?

The key age segments in the colorectal cancer market are 18-29 years, 30-39 years, 40-49 ears, 50-59 years, 60-69 years, 70-79 years, >80 years. In 2021, for the 8MM combined, adults ages 70–79 years contributed the highest proportion of the diagnosed incident cases of CRC.

Colorectal cancer market, by age group

For more age group insights, download a free report sample

What are the key stages in the colorectal cancer market?

The key stages in the colorectal cancer market are stage I, stage II, stage III, and stage IV. In the 8MM, the highest number of diagnosed incident cases of CRC was in stage II, followed by stage III and stage I.

Colorectal cancer market, by stages

For more stage insights, download a free report sample

Scope

• The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).
• The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the American Joint Committee on Cancer (AJCC) stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I–III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC.
• The CRC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

• The Colorectal Cancer Epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global CRC market.
• Quantify patient populations in the global CRC market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CRC therapeutics in each of the markets covered.
• Understand magnitude of CRC population by stage at diagnosis, recurrence of stages I–III into stage IV disease, and molecular markers.